...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Potential Deals

For the shareholders it seems to me that the best situation would be for one of the 9 BP's currently involved with these trials makes an offer and then 3 or more of them end up in a bidding war. A CVR may not be the worst deal however I'd still like a one time payment with royalties continuing to ZCC from sales. Patent life is out to 2040ish.

DM did say that deals are still being done but not at the same prices as in the past. I did get the sense that there are multiple approaches be bantered around at this time. That's just speculation though. We'll have to wait until the big girl with the vocal cords starts singing.

tada 

Share
New Message
Please login to post a reply